Merit Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Merit Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Sell	20,198 -10,396	-34%	-$569K	0.01%	1013
2026 Q1	$1.73M	Buy	30,594 +6,163	+25%	+$359K	0.01%	736
2025 Q4	$1.45M	Sell	24,431 -4,339	-15%	-$236K	0.01%	767
2025 Q3	$1.56M	Buy	28,770 +5,133	+22%	+$294K	0.01%	667
2025 Q2	$1.3M	Buy	23,637 +2,824	+14%	+$166K	0.01%	668
2025 Q1	$1.47M	Buy	20,813 +15,994	+332%	+$1.08M	0.02%	518
2024 Q4	$317K	Buy	+4,819	New	+$323K	0.01%	905

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Merit Financial Group's BMRN Position: Q2 2026 in Review

Merit Financial Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 34% in Q2 2026, selling an estimated $569K and leaving 20,198 shares worth $1.16M. The position accounts for 0.01% of the portfolio, ranked #1013.

Merit Financial Group first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.73M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Merit Financial Group held 20,198 shares of BioMarin Pharmaceuticals worth $1.16M as of Q2 2026.
Merit Financial Group sold 10,396 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $569K.
BioMarin Pharmaceuticals made up 0.01% of Merit Financial Group's portfolio in Q2 2026, its #1013 holding.
Merit Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Merit Financial Group's BioMarin Pharmaceuticals position peaked at $1.73M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.